Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase II trial
The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years of age.
The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years of age.
What's Your Reaction?
